down arrow

Sumitomo Pharma Co., Ltd.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3495000006
JPY
2,311.00
-110 (-4.54%)

Dec 11

TKS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2,302.502,459.50

52 Week

500.002,765.00
Valuation
Technical
Day's Volume

CASH

6.79 M

Shareholding (Jun 2024)

FII

0.01%

Held by 1 FIIs

DII

99.99%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a growth in Net Profit of 364.02%, the company declared Outstanding results in Jun 25

  • The company has declared positive results for the last 2 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at JPY 41,361 MM
  • NET SALES(HY) At JPY 213,651 MM has Grown at 25.53%
  • ROCE(HY) Highest at 11.22%
2

With ROE of 13.95%, it has a attractive valuation with a 1.92 Price to Book Value

3

Market Beating performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

JPY 720,597 Million (Mid Cap)

stock-summary
P/E

14.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.06%

stock-summary
Debt Equity

1.64

stock-summary
Return on Equity

10.73%

stock-summary
Price to Book

4.09

Revenue and Profits:
Net Sales:
108,002 Million
(Quarterly Results - Jun 2025)
Net Profit:
11,206 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
37.89%
0%
37.89%
6 Months
155.64%
0%
155.64%
1 Year
277.61%
0%
277.61%
2 Years
402.39%
0%
402.39%
3 Years
117.81%
0%
117.81%
4 Years
72.98%
0%
72.98%
5 Years
74.28%
0%
74.28%

Sumitomo Pharma Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Sumitomo Pharma Hits Day Low of JPY 1,719 Amid Price Pressure

Sumitomo Pharma Hits Day Low of JPY 1,719 Amid Price Pressure

Sumitomo Pharma Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Despite a strong annual return, the company faces profitability challenges, highlighted by a low Return on Equity and a negative EBIT to Interest ratio, indicating difficulties in managing its debt.

Read More
Sumitomo Pharma Hits Day Low of JPY 1,707 Amid Price Pressure

Sumitomo Pharma Hits Day Low of JPY 1,707 Amid Price Pressure

Sumitomo Pharma Co., Ltd. saw a notable decline in its stock price, contrasting with the modest decrease of the Japan Nikkei 225. Despite recent challenges, the company has shown strong annual performance, with significant returns and solid financial metrics, including a notable operating cash flow and return on equity.

Read More
Sumitomo Pharma Hits Day High with 7.41% Surge in Stock Price

Sumitomo Pharma Hits Day High with 7.41% Surge in Stock Price

Sumitomo Pharma Co., Ltd. has shown strong stock performance, with a notable increase on September 30, 2025. The company reported significant financial metrics, including a substantial operating cash flow and impressive half-year net sales growth. Despite some long-term challenges, its current valuation remains appealing in the pharmaceuticals sector.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-3.75%
EBIT Growth (5y)
-15.63%
EBIT to Interest (avg)
-8.65
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.67
Sales to Capital Employed (avg)
0.65
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
3.30%
ROE (avg)
4.62%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
1.92
EV to EBIT
40.70
EV to EBITDA
15.00
EV to Capital Employed
1.34
EV to Sales
1.52
PEG Ratio
0.12
Dividend Yield
0.12%
ROCE (Latest)
3.30%
ROE (Latest)
13.95%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 2.23% vs -6.03% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 364.02% vs -95.48% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "108,002.00",
          "val2": "105,649.00",
          "chgp": "2.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "25,261.00",
          "val2": "9,094.00",
          "chgp": "177.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9,053.00",
          "val2": "7,451.00",
          "chgp": "21.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "11,206.00",
          "val2": "2,415.00",
          "chgp": "364.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "185.70%",
          "val2": "31.10%",
          "chgp": "15.46%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 26.79% vs -43.38% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 107.50% vs -225.63% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "398,832.00",
          "val2": "314,558.00",
          "chgp": "26.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "47,984.00",
          "val2": "36,290.00",
          "chgp": "32.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "8,558.00",
          "val2": "4,277.00",
          "chgp": "100.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7,497.00",
          "val2": "-352,719.00",
          "chgp": "97.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "23,635.00",
          "val2": "-314,929.00",
          "chgp": "107.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "56.20%",
          "val2": "-4.70%",
          "chgp": "6.09%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
108,002.00
105,649.00
2.23%
Operating Profit (PBDIT) excl Other Income
25,261.00
9,094.00
177.78%
Interest
9,053.00
7,451.00
21.50%
Exceptional Items
0.00
0.00
Consolidate Net Profit
11,206.00
2,415.00
364.02%
Operating Profit Margin (Excl OI)
185.70%
31.10%
15.46%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 2.23% vs -6.03% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 364.02% vs -95.48% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
398,832.00
314,558.00
26.79%
Operating Profit (PBDIT) excl Other Income
47,984.00
36,290.00
32.22%
Interest
8,558.00
4,277.00
100.09%
Exceptional Items
-7,497.00
-352,719.00
97.87%
Consolidate Net Profit
23,635.00
-314,929.00
107.50%
Operating Profit Margin (Excl OI)
56.20%
-4.70%
6.09%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 26.79% vs -43.38% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 107.50% vs -225.63% in Mar 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Sumitomo Pharma Co., Ltd. stock-summary
stock-summary
Sumitomo Pharma Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."